网站大量收购独家精品文档,联系QQ:2885784924

多重耐药医院感染的预防和控制.ppt

  1. 1、本文档共95页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
多重耐药医院感染的预防和控制

In HA hospitals, isolation precautions should be implemented to break the transmission of infections. The elements includes hand hygiene, PPE, patient placement, decontamination, waste management, linen and laundry, and patient transport. Each of them will be discussed in the following presentation. Reference: Hospital Authority Infection Control Plan for Avian Influenza version 4.01. From http://ha.home/idctc/document/r_no_9_-_ha_infection_control_plan.pdf * * * * * * * The “12 Steps to Prevent Antimicrobial Resistance: Hospitalized Adults” intervention program is the first “12 Steps” to be launched because hospital patients are at especially high risk for serious antimicrobial-resistant infections. Each year nearly 2 million patients in the United States get an infection in a hospital. Of those patients, about 90,000 die as a result of their infection. More than 70% of the bacteria that cause hospital-acquired infections are resistant to at least one of the drugs most commonly used to treat them. Persons infected with antimicrobial-resistant organisms are more likely to have longer hospital stays and require treatment with second-or third-choice drugs that may be less effective, more toxic, and/or more expensive. * * * * * 我们又用PFGE的方法对这些细菌做了同源性分析。PFGE因为在后面会讲到,这里我们暂时不讲,大家只要知道它是一种同源性分析的方法。 T7、T8的条带基本相同,通常我们认为他们来源相同或相似。而T10和T11的条带有明显差异,所以但从肉眼,就能判断他们没有相关性,来源不同。 * Different types of surface disinfectant and their pros and cons. Factors that need to be concerned when selecting surface disinfectants The use of an Environmental Protection Agency (EPA)-registered product with proven efficacy claims is crucial t selection of the appropriate product. * * * * * * * * * * * Draft: Not Approved for Use IVZ 2008-W-1277602-SS MS* Ref 1/Badal 2008, p 1, ?2, L1,2; p 4, Fig 1 Ref 1/Badal 2008, p 1, Title Ref 1/Badal 2008, p 1, ?2, L1,2; p 4, Conclusions, ?1, L1,2, ?2, L1,2 Ref 1/Badal 2008, p 15, Conclusions, ?1, ?2 Reference Badal R, Bouchillon S, Hoban D, et al. Gl

文档评论(0)

shenlan118 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档